Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGossamer Bio Inc

Gossamer Bio Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
11.11 USD -0.58 ( 4.96%)
Last update at 2026-11-12T15:39:00Z
VOLUME
29999
Market Cap
63.43M

Momentum Score

…

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
10.60
Low
11.27
High
52 Week Price Range
9.12
Low
309.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Gossamer Bio is a clinical-stage biopharmaceutical company developing therapies that target immunology, inflammation and oncology. Long-term growth could be driven by advancement of its clinical-stage programs, regulatory approvals, strategic partnerships and successful commercialization, which may benefit from unmet needs in its target indications.
Principal investment risks include clinical trial failures, regulatory setbacks, ongoing cash burn with potential need for additional financing, intense competition and intellectual property challenges.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
11.69
Dividend Yield
-
Revenue TTM
53.29M
Revenue Per Share
16.81
Gross Profit TTM
53.29M
Debt / Equity
-1.65
ROE
-783.37%
Net Debt
164.24M
ROCE
-150.03%
Diluted EPS TTM
-52.80

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -170.46M -55.63M -179.82M -229.38M -234.00M
Net income -170.37M -56.53M -179.82M -240.23M -249.08M
Selling general administrative 37.63M 36.13M 38.45M 47.61M 45.78M
Selling and marketing expenses - - 2.78M - -
Gross profit 47.47M 114.70M -4.38M - -
Reconciled depreciation 1.00M 4.15M 4.50M 4.43M 5.17M
Ebit -163.25M -44.12M -166.31M -218.59M -216.12M
Ebitda -162.25M -39.97M -161.92M -215.43M -214.49M
Depreciation and amortization 1.00M 4.15M 4.38M 3.16M 1.64M
Non operating income net other - - - 3.10M 1.56M
Operating income -163.25M -59.92M -183.76M -218.59M -216.12M
Other operating expenses 211.72M 174.62M 183.76M 218.53M 216.05M
Interest expense 10.99M 11.52M 13.51M 13.88M 19.44M
Tax provision -0.09M 0.89M 0.00M - -
Interest income 1.97M 1.78M 2.28M 1.58M 0.76M
Net interest income -9.02M -9.74M -11.45M -12.30M -18.68M
Non recurring - - - -0.07M -0.07M
Income tax expense -0.09M 0.89M 10.00M 10.85M 15.07M
Total revenue 48.47M 114.70M 0.00M 0.00M 0.00M
Total operating expenses 210.72M 174.62M 183.76M 218.53M 216.05M
Cost of revenue 1.00M 4.15M 4.38M - -
Total other income expense net -7.21M 4.28M 3.94M -10.79M -17.88M
Net income from continuing ops -170.37M -56.53M -187.43M -229.38M -234.00M
Net income applicable to common shares - - - -229.38M -234.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 172.25M 315.29M 311.92M 272.45M 343.66M
Other current assets 18.18M 10.03M 10.09M 6.20M 6.50M
Total liab 295.01M 285.80M 249.15M 260.37M 222.19M
Total stockholder equity -122.76M 29.49M 62.77M -1032.22M -811.53M
Other current liab 56.54M 24.68M 31.16M 33.17M 33.71M
Common stock 0.02M 0.02M 0.02M 0.01M 0.01M
Capital stock 0.02M 0.02M 0.02M 0.01M 0.01M
Retained earnings -1438.94M -1268.57M -1212.04M -1032.22M -811.53M
Other assets - - 0.00M 0.68M 1.08M
Cash 37.73M 46.07M 32.11M 111.97M 183.40M
Total current liabilities 63.44M 45.01M 51.60M 49.23M 39.86M
Current deferred revenue - 17.05M - - -
Net debt 164.24M 156.81M 180.35M 113.77M 1.83M
Short term debt 0.94M 0.96M 14.91M 14.60M 2.90M
Short long term debt - - 11.61M 11.61M -
Short long term debt total 201.97M 202.88M 212.46M 225.74M 185.24M
Other stockholder equity 1321.30M 1296.85M 1275.14M 0.56M -0.05M
Property plant equipment - - - 3.98M 5.32M
Total current assets 167.64M 309.89M 306.52M 261.88M 331.78M
Net tangible assets - - - 12.08M 121.46M
Short term investments 99.20M 248.44M 264.32M 143.71M 141.81M
Net receivables 12.53M 5.34M - - 0.20M
Long term debt 198.51M 197.52M 197.41M 207.70M 179.12M
Accounts payable 5.96M 2.32M 5.53M 1.46M 3.24M
Accumulated other comprehensive income -5.15M 1.19M -0.35M -0.57M 0.04M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -1032.22M -811.53M
Non currrent assets other 0.41M 0.28M 0.62M 0.68M 1.08M
Non current assets total 4.61M 5.40M 5.40M 10.57M 11.88M
Capital lease obligations 4.40M 5.36M 3.45M 6.43M 6.12M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 156.44M 29.02M -88.14M -0.56M -115.81M
Change to liabilities - - - -1.85M -4.00M
Total cashflows from investing activities 156.36M 29.02M -110.97M -1.03M -117.43M
Net borrowings 0.00M -12.58M -11.61M -5.81M -5.81M
Total cash from financing activities 6.42M -11.49M 190.15M 117.09M 3.33M
Change to operating activities - - - -2.65M 5.20M
Net income -170.37M -56.53M -179.82M -229.38M -234.00M
Change in cash -8.34M 13.96M -79.86M -71.49M -303.15M
Begin period cash flow 46.07M 32.11M 111.97M 183.47M 486.62M
End period cash flow 37.73M 46.07M 32.11M 111.97M 183.47M
Total cash from operating activities -171.27M -3.47M -159.16M -187.03M -188.89M
Issuance of capital stock 0.00M 0.00M 201.34M 119.95M 0.00M
Depreciation 1.00M 4.15M 4.38M 4.43M 5.17M
Other cashflows from investing activities - - - -0.07M -0.07M
Change to account receivables -6.89M -5.34M - - -
Sale purchase of stock - 0.63M 0.44M 122.90M 3.33M
Other cashflows from financing activities - 1.09M 0.89M 2.95M 3.33M
Change to netincome - - - 42.55M 32.03M
Capital expenditures 0.08M 0.00M 0.00M 0.47M 1.62M
Cash flows other operating - - - 0.06M 8.27M
Cash and cash equivalents changes - - - -70.98M -302.99M
Change in working capital -13.63M 39.46M -14.84M -4.46M 0.77M
Stock based compensation 10.55M 20.62M 28.52M 42.55M 32.01M
Other non cash items 1.18M -11.17M 2.60M -0.18M 6.81M
Free cash flow -171.34M -3.47M -159.16M -187.51M -190.51M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GOSS
Gossamer Bio Inc		 -0.58
4.96%		 11.11 - - 1.19 2.66 0.92 -0.39
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

3115 Merryfield Row, San Diego, CA, United States, 92121

858 684 1300

https://www.gossamerbio.com

161

Name Title Year Born
Mr. Faheem Hasnain Co-Founder, CEO, Pres & Chairman 1958
Mr. Bryan Giraudo COO & CFO 1975
Mr. Christian Waage Exec. VP of Technical Operations & Admin. 1967
Dr. Laura L. Carter Ph.D. Chief Scientific Officer 1967
Mr. Jeff Boerneke Gen. Counsel & Sec. NA
Ms. Deanna Weber Sr. VP of HR NA
Dr. Richard Aranda M.D. Chief Medical Officer 1960
Mr. Mario Orlando Sr. VP of Commercial New Product Planning NA
Ms. Caryn L. Peterson Exec. VP of Regulatory Affairs 1959
Mr. Matt Cravets Sr. VP of Biometrics NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…